Biodegradable Elastomer Processing at Low Temperatures
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for fabricating thermoplastic, biodegradable elastomers for medical devices at temperatures below 100°C are not feasible without compromising the bioactivity of bioactive agents, as existing polymers either lose bioactivity at high temperatures or require processing conditions that are not compatible with temperature-sensitive materials.
Innovation Solution
Development of block copolymers comprising a polycaprolactone (PCL) block and an amorphous block with a glass transition temperature less than 30°C, allowing for thermal processing at temperatures below 100°C while maintaining bioactivity, such as through the combination of PMVL and PCL to form triblock polymers that are both biodegradable and elastomeric.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing thermoplastic elastomers are processed at conventional temperatures, then processing is feasible, but bioactivity of encapsulated agents is lost
Solution Approach 1:
The patent changes the thermal parameters of the elastomer by incorporating PCL blocks with low melting points (50-60°C) and amorphous blocks with low glass transition temperatures (less than 30°C). This parameter change enables processing at temperatures below 100°C, preserving bioactivity while maintaining processability through thermoplastic methods
Solution Approach 2:
The patent creates composite block copolymers combining PCL (polycaprolactone) blocks with amorphous elastomeric blocks (such as poly(β-methyl-δ-valerolactone)). This composite structure integrates the low melting point advantage of PCL with the elastomeric properties of the amorphous block, enabling low-temperature thermoplastic processing while maintaining rubber-like mechanical properties
2Reliability
If thermoplastic processing is performed at low temperatures, then bioactivity is preserved, but conventional polymers cannot be processed
Solution Approach 1:
The patent modifies the thermal transition parameters of the polymer by designing block copolymers with PCL blocks (melting point 50-60°C) and amorphous blocks with Tg less than 30°C. These parameter changes enable the material to undergo thermoplastic processing at low temperatures (below 100°C) while maintaining sufficient chain mobility and processability
Solution Approach 2:
The patent segments the polymer into distinct functional blocks: crystalline PCL blocks that melt at low temperatures providing thermoplasticity, and amorphous elastomeric blocks providing rubber-like properties. This segmentation allows each block to contribute its specific thermal characteristics, enabling low-temperature processing while maintaining elastomeric functionality
3Temperature
If conventional elastomers are used, then elastomeric properties are maintained, but low-temperature processing is not achievable
Solution Approach 1:
The patent creates composite block copolymers where PCL blocks provide low-temperature melting (50-60°C) for thermoplastic processing, while amorphous elastomeric blocks (such as poly(β-methyl-δ-valerolactone) with Tg less than 30°C) provide rubber-like elasticity and mechanical properties. The synergistic combination maintains elastomeric strength at low processing temperatures
Solution Approach 2:
The patent assigns different local functions to different blocks within the copolymer: PCL blocks localized for low-temperature melting and thermoplasticity, and amorphous blocks localized for providing elastomeric properties. This local quality differentiation allows the material to exhibit both low processing temperature and maintained elastomeric strength simultaneously
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the processing of biodegradable elastomers at low temperatures, preserving bioactivity and allowing for the encapsulation of bioactive agents, which can be used in medical devices and 3D printing without exposing them to high temperatures, thus maintaining their effectiveness.
Implementation Method 1
a second block being amorphous and having a glass transition temperature less than 30° C.
Implementation Method 2
subjecting the block copolymer to thermal processing at a temperature less than 100° C.
Data Source
AI summary
Methods including providing a block copolymer, the block copolymer comprising at least a polycaprolactone (PCL) block; and a second block being amorphous and having a glass transition temperature less than 30° C.; and subjecting the block copolymer to thermal processing at a temperature less than 100° C. Articles and thermoprocessing methods utilizing such block copolymers are also disclosed herein.